Boan Biotech, a subsidiary of Luye Pharma Group, announced today that it has signed a Memorandum of Understanding with Merck, a world-leading science and technology company, under which the two partie...
Clinical trials of the drug in Europe and the U.S. are making good progressOctober 13, 2021, Shanghai -- Luye Pharma Group announced that the marketing authorization application for the Denosumab Inje...
Luye Pharma Group today announced that BA1105, a novel antibody developed by its subsidiary Boan Biotech, has been approved by the Center for Drug Evaluation (CDE) of China's National Medical Prod...
September 27, 2021, Shanghai, China – Luye Pharma Group today announced that Dulaglutide Injection (BA5101) developed in-house by Boan Biotech, a subsidiary of the Group, has obtained approval f...
September 26, 2021, Boston, USA - Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific anti...
Boan Biotech has announced significant progress with LY-CovMab, a neutralizing antibody independently developedfor the treatment of COVID-19. LY-CovMab has been preliminarily validated for effectively...
Luye Pharma Group today announced that Boyounuo (Bevacizumab Injection), an oncology biologic developed in-house by its subsidiary Boan Biotech, has been approved by China’s National Medical Pro...
Luye Pharma Group’s subsidiary Boan Biotech recently published research results for its innovative in-house bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) in Antibody Therapeutic...
博优诺®(Bevacizumab Injection), an anticancer drug developed by Boan Biotech, a subsidiary of Luye Pharma Group, was launched in China on June 5, 2021. The first product from Boan Biotech’s pipe...
Luye Pharma Group announced today that its holding subsidiary, Boan Biotech, has signed an agreement with AstraZeneca China regarding the promotion rights to the anticancer drug 博优诺® (Bevacizumab I...
Follow me
鲁公网安备37069102000284